Vyant Bio (VYNT) Reports Q1 Loss from Cont. Operations of $0.15

Go back to Vyant Bio (VYNT) Reports Q1 Loss from Cont. Operations of $0.15

Interpace Biosciences Announces First Quarter 2022 Financial and Business Results

May 16, 2022 4:15 PM EDT

 Q1 Revenue of $10.4 million up 6% versus Prior Year Q1 Net Loss improved $2 million versus Prior... More